Investigating the recognition of a novel ligand by gamma-delta T cells and the translation of this interaction into molecules for future cancer immunotherapy

Informazioni relative al progetto

gdTCR-Ligand

ID dell’accordo di sovvenzione: 749010

DOI 10.3030/749010

Progetto concluso

Data della firma CE 10 Maggio 2017

Data di avvio 1 Giugno 2017

Data di completamento 31 Maggio 2019

Finanziato da

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Costo totale € 177 598,80

Contributo UE € 177 598,80

Coordinato da

UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Netherlands

Obiettivo

Gamma-delta (gd-)T cells are a fast acting subset of T cells that recognize a wide variety of ligands. In contrast to alpha-beta T cells they are not restricted to classical peptide-MHC antigens. Our preliminary data on a gd-T cell clone shows selective recognition of tumour cells mediated through a novel ligand.
The aims of this action are; 1) elucidating the molecular mechanism of the gd-T cell receptor (TCR) recognizing the novel ligand on cancer cells and 2) generating therapeutic agents for cancer cells.
A multidisciplinary approach will be used to unveil the interaction of the gd-TCR with its ligand. The gd-TCR and novel ligand molecules will be made using recombinant expression. These proteins will be used to characterize this interaction in detail by determining the affinity and the crystal structure. The results generated in this part of the action will increase the current knowledge regarding gd-T cell ligands.
The researcher will reintegrate in his home country using his skills in structural immunology, which he acquired in the Rossjohn laboratory at Monash University in Australia, to address the molecular mechanism of the gd-TCR ligand interaction. Additionally, he will be trained by the host laboratory in in vitro and in vivo immunological assays.

Campo scientifico

• engineering and technology › materials engineering › crystals
• natural sciences › biological sciences › biochemistry › biomolecules › proteins
• medical and health sciences › clinical medicine › oncology
• medical and health sciences › basic medicine › immunology › immunotherapy

Programma(i)

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Argomento(i)

• MSCA-IF-2016 - Individual Fellowships

Invito a presentare proposte

H2020-MSCA-IF-2016

Meccanismo di finanziamento

MSCA-IF-EF-RI - RI – Reintegration panel

Coordinatore

UNIVERSITAIR MEDISCH CENTRUM UTRECHT

• Contribution nette de l'UE: € 177 598,80
• Indirizzo: HEIDELBERGLAAN 100 ; 3584 CX Utrecht ; Paesi Bassi
• Regione: West-Nederland › Utrecht › Utrecht
• Tipo di attività: Higher or Secondary Education Establishments
• Costo totale: € 177 598,80